AzTrials
AzTrials

Lumbar Spinal StenosisNCT07588555

Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial

A study testing LUSE-TLIF and MIS-TLIF in people with Lumbar Spinal Stenosis, run by The Third Affiliated Hospital of Southern Medical University at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. Read more about this study

Who is it for?
Ages 40 to 70 years
Conditions the study is for
Lumbar Spinal Stenosis
What is being tested?
LUSE-TLIF and MIS-TLIF
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
276 participants
Where
1 siteChina
Study dates
18 Mar 2026to 31 Dec 2031
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ranging from 40 to 70 years, irrespective of sex.
  • Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain.
  • Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and/or lumbar instability.
  • Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months.
  • Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule.

Who cannot join

  • Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound.
  • Patients with a history of previous lumbar spine surgery.
  • Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases.
  • Pregnancy or lactation.
  • Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure.
  • Known concurrent diseases considered by the investigator to preclude study entry.
  • Inability to comply with study assessments or complete questionnaires for any reason.
  • Patients deemed unsuitable for participation in this trial as judged by the investigator.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Kaiting Chen, PhD contact

+86 020-62784332

1190011049@smu.edu.cn

China1 site, 1 recruiting
  • The Third Affiliated Hospital of Southern Medical University

    Guangzhou, Guangdong, 515000

    Kaiting Chen, PhD, +86 020-62784332, 1190011049@smu.edu.cn

    Recruiting

Other trials in China

About this study

Official title: Comparative Analysis of L-Unitary Soft Endoscope Transforaminal Lumbar Interbody Fusion (LUSE-TLIF) Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial

Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. For patients who do not respond to conservative treatment, surgical intervention remains a key therapeutic approach, with lumbar interbody fusion (LIF) being a commonly employed procedure. The technique has evolved from posterior lumbar interbody fusion (PLIF) to transforaminal lumbar interbody fusion (TLIF) and, more recently, to minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Although MIS-TLIF can effectively reduce tissue trauma and complications, it still faces clinical challenges such as intraoperative visual blind spots and the potential for postoperative chronic back pain associated with reliance on conventional pedicle screws. To address these limitations, our research team independently developed a highly integrated, miniaturized (with an outer diameter of only 1.8 mm), and maneuverable L-Unitary Soft Endoscope (LUSE) minimally invasive system. Its unique design helps avoid obstruction of the surgical field and allows flexible adjustment during the procedure. Currently, there is a lack of clinical efficacy evaluations in China on the use of this LUSE system for TLIF surgery (referred to as LUSE-TLIF) in treating LSS. Therefore, this study aims to systematically compare LUSE-TLIF with the currently mainstream MIS-TLIF, evaluating its safety, efficacy, and clinical outcomes in the treatment of LSS, in order to provide spine surgeons with a novel and potentially superior minimally invasive surgical option.

Read the detailed description

Lumbar spinal stenosis (LSS) is a common degenerative condition of the lumbar spine. In its narrow definition, LSS primarily refers to central canal stenosis resulting from facet joint hypertrophy and thickening of the ligamentum flavum. Broadly, it also encompasses lateral recess stenosis and bony stenosis within the intervertebral foramen region, categories that some scholars group under lateral canal stenosis. The main symptoms of LSS include low back pain, leg pain, and neurogenic claudication, which impair patients' quality of life and severely limit function, particularly in the elderly. With the aging global population, the prevalence of LSS is rising, affecting approximately 103 million patients worldwide. Treatment options for LSS include both conservative and surgical management. Conservative treatments encompass medication, physical therapy, and lifestyle modifications. However, surgical intervention may be necessary for LSS patients who do not respond adequately to conservative therapies.

Lumbar interbody fusion (LIF) is commonly employed to treat various spinal pathologies, particularly lumbar spinal stenosis. Currently, LIF can be performed via open or minimally invasive approaches, including transforaminal, posterior, anterior, and lateral routes, each with its own advantages and disadvantages. Generally, posterior lumbar interbody fusion (PLIF) is a well-established procedure associated with good fusion rates and relatively low complication rates. However, it carries the risk of iatrogenic injury to neural structures and paraspinal muscles. Despite demonstrating favorable early outcomes, PLIF has notable limitations, including a relatively high complication rate and a challenging recovery process. In 1982, transforaminal lumbar interbody fusion (TLIF) was introduced, which offers a less traumatic and safer unilateral interbody fusion technique. TLIF addresses several shortcomings of PLIF, leading to its rapid adoption and continuous refinement within the spine surgery community. Nevertheless, traditional open TLIF faces challenges such as significant tissue trauma, potential muscle atrophy, chronic postoperative low back pain, and adjacent segment instability.

The advent of various minimally invasive techniques has helped reduce muscle injury and irritation to the posterior spinal elements. To minimize surgical trauma and facilitate rapid recovery, minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) was developed. A meta-analysis published in 2017 reported that MIS-TLIF could lower postoperative complication rates compared to conventional open procedures. Furthermore, MIS-TLIF demonstrates significant efficacy in protecting muscles (e.g., the multifidus) and ligaments. A comparative study indicated that the rates of postoperative complications and reoperations at 2-year and 3-year follow-ups were significantly lower for MIS-TLIF than for traditional TLIF. However, despite the improved visualization provided by the endoscope in MIS-TLIF, visual blind spots may still exist in certain complex anatomical areas, potentially leading to incomplete assessment of the pathological site and suboptimal placement of internal fixation devices. Additionally, MIS-TLIF relies on traditional open pedicle screw fixation, which may increase the long-term risk of postoperative chronic low back pain.

To address the aforementioned clinical challenges, our research team independently developed a L-Unitary Soft Endoscope minimally invasive system, termed LUSE (Chinese National Invention Patent: CN117017466B). It completed filing as a Class I medical device with the Guangzhou Market Supervision Administration in 2021 (Filing No.: 20210598) and is classified as a set of fundamental orthopedic surgical instruments, with its filing status remaining valid. The system features a highly integrated, all-in-one design that combines key components such as the display, camera, light source, and transmission system into a single unit, simplifying operation and maintenance. During development, particular attention was paid to controlling the size and weight of the endoscope, resulting in a compact and lightweight soft endoscope with a diameter of 1.8 mm and a length of 2-4 cm. Its volume and weight are reduced by approximately 93% compared to traditional endoscopes. This endoscope integrates multiple functions including illumination, imaging, and recording, significantly enhancing procedural convenience and patient comfort.

Compared to the traditional MIS-TLIF performed under a Quadrant expandable retractor system, the highly integrated LUSE system offers several advantages in lumbar minimally invasive fusion surgery: (1) The LUSE system supports 8K ultra-high-definition imaging, providing clear and detailed visualization of the surgical field, whereas the Quadrant retractor system only provides illumination without endoscopic magnification, limiting the ability to visualize fine anatomical structures; (2) LUSE-TLIF utilizes a percutaneous pedicle screw system, minimizing injury to the lumbar back muscles, ligaments, and blood vessels. In contrast, MIS-TLIF requires the placement of pedicle screws via a traditional open approach, which may increase the long-term incidence of chronic back pain; (3) The soft lens of the LUSE system offers 360-degree flexibility, whereas the Quadrant retractor system has inherent visual blind spots that can hinder adequate decompression and optimal implant placement. Therefore, LUSE-TLIF holds multiple advantages over MIS-TLIF. Our team has previously demonstrated the safety and efficacy of the LUSE system in anterior cervical discectomy and fusion (ACDF) and artificial disc replacement (ADR) procedures, with related studies published in leading Chinese journals such as the Chinese Journal of Orthopaedicsand the Chinese Journal of Spine and Spinal Cord. However, there is currently a lack of clinical research in China evaluating the efficacy of LUSE-TLIF for treating LSS. Consequently, this study aims to apply LUSE-TLIF for LSS treatment, observe its safety, efficacy, and clinical outcomes, and conduct a comparative analysis with MIS-TLIF, with the goal of providing spine surgeons with an additional and potentially superior surgical option.

Being tested
LUSE-TLIF, MIS-TLIF
Keywords
Lumbar spinal stenosis, LUSE-TLIF, MISTLIF, Lumbar Spondylolisthesis, Lumbar Instability
Medical subject headings
Spinal Stenosis, Spondylolisthesis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LUSE-TLIFProcedure or surgery

    Also called Experimental Group, 01

    LUSE-TLIF is a TLIF procedure performed through the LUSE system.

  • MIS-TLIFProcedure or surgery

    Also called Control group, 02

    MIS-TLIF is a TLIF procedure performed through the Quadrant channel and other systems.

Study groups in NCT07588555
Study groupRoleWhat they receive
LUSE-TLIFExperimentalThe subject underwent LUSE-TLIF surgery
Receives: Procedure: LUSE-TLIF
MIS-TLIFActive comparatorSubjects underwent MIS-TLIF surgery assisted by the Quadrant channel
Receives: Procedure: MIS-TLIF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vertebral Fushion

    Assess vertebral fusion status through imaging indicators and clinical symptoms. Vertebral fusion was established as the clinical outcome, defined as: (1) Clinical fusion: a. absence of mechanical low back pain and intermittent claudication; b. dynamic flexion-extension radiographs demonstrating motion angle of the surgical segment less than 4°; (2) Bony fusion: a. Bridwell grade A or B; b. increase in segmental lordosis angle of the surgical segment ≥3° compared to baseline; (3) simultaneous achievement of both clinical and bony fusion.

    Measured: 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

  2. ODI

    The ODI score refers to the Oswestry Disability Index, a widely used questionnaire that measures the level of disability in individuals with low back pain. It consists of ten sections assessing daily activities, with scores ranging from 0 to 100; higher scores indicate more severe disability.

    Measured: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

Secondary outcomes (10)
  1. VAS

    The VAS score refers to the Visual Analogue Scale, a tool used to measure leg and back pain intensity. Patients mark a point on a 10-cm line, where one end represents "no pain" (0) and the other "worst imaginable pain" (10). The distance from the zero point gives the score, providing a simple, quick measure of symptom severity.

    Measured: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

  2. Surgery time

    The surgery duration is recorded according to the time in the surgical document, with the unit in minutes.

    Measured: within 24 hours after surgery

  3. Total blood loss

    Collect the patient's height (m), weight (kg), hematocrit levels one day before and one day after surgery, and calculate the total blood loss (mL) using the Gross equation and Nadler formula.

    Measured: within 24 hours after surgery

  4. postoperative drainage volume

    The total drainage volume (mL) will be recorded by a ward nurse who is unaware of the study

    Measured: Within 24 hours after the subject is discharged

  5. incision length

    The incision length (cm) will be measured by a surgical nurse who is unaware of the study.

    Measured: Within 24 hours after surgery

  6. surgical costs

    Hospitalization costs (yuan/¥) will be calculated by a nurse who is unaware of the study, based on hospital system records.

    Measured: Within 24 hours after the subject is discharged

  7. intraoperative blood loss

    Intraoperative blood loss was recorded by a nurse who was unaware of this study, including blood in the drains and in the gauze, measured in mL.

    Measured: within 24 hours after surgery

  8. Other lumbar spine imaging indicators

    Measurement of dural sac cross-sectional area, lumbar spondylolisthesis rate, Cobb angle, average intervertebral disc height, and other parameters using X-ray, CT, and MRI.

    Measured: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

  9. Condition of paraspinal muscles

    MRI measures paraspinal muscle area and fat infiltration rate by analyzing cross-sectional images from the lumbar spine.

    Measured: baseline, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

  10. Muscle injury

    CK (creatine kinase) and CK-MB are blood biomarkers used to assess muscle damage after lumbar fusion surgery

    Measured: 1 day before surgery, 1 day and 3 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2026
  2. Study start18 Mar 2026
  3. Primary completion31 Dec 2031 (estimated)
  4. Study completion31 Dec 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a prospective, single-center, randomized, controlled clinical trial. Patients with lumbar spinal stenosis were screened according to the predefined inclusion and exclusion criteria and enrolled after providing written informed consent. Eligible participants were randomly assigned in a 1:1 ratio to either the LUSE-TLIF group or the MIS-TLIF group by a study nurse (who was not involved in patient recruitment, intervention delivery, or outcome assessment) using a computer-generated randomization scheme. Patients in the two groups underwent LUSE-TLIF or MIS-TLIF, respectively. General patient characteristics, perioperative data, radiographic parameters, and postoperative complications were recorded. The efficacy and safety of the two approaches were subsequently evaluated.
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
276 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07588555
Sponsor's protocol ID
LUSETLIFvsMISTLIF
Other IDs
MR-44-26-026507
Status last verified
Mar 2026
First submitted
24 Apr 2026
Last updated
14 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Study Protocol, Statistical Analysis Plan, Informed Consent Form

Questions about this trial

What is this clinical trial studying?

A study testing LUSE-TLIF and MIS-TLIF in people with Lumbar Spinal Stenosis, run by The Third Affiliated Hospital of Southern Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kaiting Chen, PhD (+86 020-62784332, 1190011049@smu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vertebral Fushion (time frame: 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in